"Wegovy: FDA Approval for Heart Health Benefits Signals Potential Insurance Coverage Expansion"

The FDA has approved Novo Nordisk's weight loss drug Wegovy for reducing the risk of serious cardiovascular complications in adults with obesity and heart disease, marking the first time a weight loss medication has gained expanded use for preventing life-threatening cardiovascular events. The approval could expand insurance coverage for the costly drug and similar treatments for obesity. Wegovy, which mimics a gut hormone to suppress appetite, showed a 20% reduction in the overall risk of heart attack, stroke, and death from cardiovascular causes in a landmark phase three trial. This move could also help Novo Nordisk maintain its lead over competitors in the weight-loss drug market.